Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population Meeting Abstract
| Authors: | Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; Fogliatto, L. M.; Kim, D. D. H.; le Coutre, P.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N. A.; Chee, L. C. Y.; Gutiérrez, V. G.; Sasaki, K.; De Moura Freitas, C. M. B.; Kapoor, S.; Espurz, N.; Dhamal, V.; Rea, D. |
| Abstract Title: | Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4536 |
| Language: | English |
| ACCESSION: | WOS:001159740308025 |
| DOI: | 10.1182/blood-2023-186854 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
